Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.
Sanofi has decided to abandon development of Regulus Therapeutics’s lademirsen against a rare kidney disease after it failed to show benefit in an interim analysis.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.
The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
The company said the main reason for expanding its manufacturing capacity was its growing US commercial portfolio and clinical pipeline.
